News

Indegene announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 2.25 per equity Share (i.e. 112.5%) , subject to the approval of the shareholders.

Net profit of Indegene declined 32.23% to Rs 79.70 crore in the quarter ended March 2026 as against Rs 117.60 crore during the previous quarter ended March 2025. Sales rose 32.80% to Rs 1003.40 crore in the quarter ended March 2026 as against Rs 755.60 crore during the previous quarter ended March 2025.For the full year,net profit declined 1.38% to Rs 401.10 crore in the year ended March 2026 as against Rs 406.70 crore during the previous year ended March 2025. Sales rose 23.64% to Rs 3510.50 crore in the year ended March 2026 as against Rs 2839.30 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1003.40755.60 33 3510.502839.30 24 OPM %16.3019.52 -17.6318.82 - PBDT167.20170.00 -2 671.70619.50 8 PBT125.40149.30 -16 545.30539.30 1 NP79.70117.60 -32 401.10406.70 -1 Powered by Capital Market - Live News

Indegene will hold a meeting of the Board of Directors of the Company on 29 April 2026.

Net profit of Indegene declined 6.20% to Rs 102.90 crore in the quarter ended December 2025 as against Rs 109.70 crore during the previous quarter ended December 2024. Sales rose 30.77% to Rs 942.10 crore in the quarter ended December 2025 as against Rs 720.40 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales942.10720.40 31 OPM %16.9318.30 - PBDT174.30166.30 5 PBT134.70146.30 -8 NP102.90109.70 -6 Powered by Capital Market - Live News

Indegene today announced that Jill DeSimone, a widely respected global life sciences leader, and Neeraj Bharadwaj, a renowned private equity leader, have joined Indegene`s Board of Directors.Jill brings over four decades of life sciences leadership, with hands-on experience building and leading large commercial and medical organizations. She has held senior leadership roles at leading biopharma companies, including President of U.S. Oncology at Merck, where she led major businesses and product franchises across global markets. She led the launch of Keytruda, Merck`s first true oncology product. Jill has also held leadership roles at Teva and Bristol Myers Squibb. She currently serves on the Boards of several public and private biotech companies and brings a valuable set of experiences to Indegene. Neeraj brings extensive experience in private equity, capital allocation, and portfolio value creation. He is currently a Senior Advisor with Carlyle Asia and previously held leadership roles at Accel Partners` growth investing operations in India and Apax Partners. He has worked closely with boards and management teams to support disciplined growth, inorganic expansion, and sustained value creation across scaled businesses, including healthcare and technology-enabled services.Powered by Capital Market - Live News